Business Wire

Kinaxis Unveils 2026 Customer Award Winners at Kinexions in Las Vegas

4.6.2026 13:00:00 CEST | Business Wire | Press Release

Share

Kinaxis® (TSX: KXS), a global leader in end-to-end supply chain planning and orchestration, today announced the winners of its 2026 Customer Awards. Now in their eighth year, these awards were celebrated live at Kinexions North America, the flagship premiere global conference hosted by Kinaxis, bringing together supply chain leaders from around the world.

The annual awards spotlight organizations and individuals who are redefining what’s possible in modern supply chains. The winners are driving innovation, responding with agility, and delivering real business results with the Kinaxis Maestro™ platform. The awards recognized seven leading companies including Reckitt, General Motors, Lupin, Jabil, and Cardinal Health among the full list of winners. Additionally, Praveen Vasudevan (Bio-Rad Laboratories) received the champion award for their industry contributions.

“Kinexions is where the best of the best in supply chain come together, and our customer award winners represent exactly what that excellence looks like in action,” said Razat Gaurav, CEO at Kinaxis. “These organizations aren’t just navigating complexity; they’re turning it into competitive advantage, using AI-driven planning and decisioning to drive measurable impact across their operations with support from Kinaxis. Their leadership, innovation, and results are setting a new benchmark for what’s possible in modern supply chains and we’re proud to recognize them on this global stage.”

2026 Kinaxis Customer Award Winners

  • Pioneer Award: Reckitt
    Recognizes organizations demonstrating a clear implementation journey and measurable supply chain impact across service, inventory, lead times, and planning performance. Recognized as a pioneer through early adoption of enterprise scheduling and the rapid implementation of demand, supply, inventory, and enterprise planning capabilities, with Kinaxis Maestro serving as the core foundation of Reckitt’s modern supply chain technology stack.
  • Champion Award: Praveen Vasudevan, BioRad Laboratories
    Honors individuals demonstrating leadership, vision, and perseverance in supply chain transformation.
    Praveen Vasudevan was recognized as a deep technical and business champion who navigates the intense complexities of the AI, life sciences, and supply chain intersection. He successfully transformed foundational data models to elevate customer-driven planning into a strategic, enterprise‑wide decision capability, directly enabling the seamless forecasting and distribution of critical medical technologies in the life sciences industry.
  • Excellence Award: General Motors
    Awarded for measurable business impact through supply chain strategy.
    Recognized for excellence in supply chain strategy and orchestration, General Motors modernized end-to-end service parts planning with Kinaxis Maestro—enabling concurrent planning, faster disruption response, and improved product availability while protecting profitability and cash flow.
  • Impact Award: Lupin Limited
    Recognizes positive environmental and social contributions.
    Recognized for leading with purpose and delivering measurable results for people and the planet. Lupin leveraged a unified planning platform across 130+ countries to reduce waste and emissions, boost employee wellbeing through automation, and expand patient access through more resilient, predictive supply chain decisions.
  • Innovation Award: Jabil
    Highlights innovative applications of Kinaxis technology.
    Recognized for innovation leadership, Jabil is an early adopter of advanced AI, machine learning forecasting, optimization, and risk intelligence—actively innovating and piloting emerging capabilities to improve planning efficiency, forecast accuracy and long‑term inventory outcomes.
  • Center of Excellence Catalyst Award: Cardinal Health
    Recognizes customers who leverage a Kinaxis Center of Excellence to accelerate adoption and scale value.
    Cardinal Health’s Global Medical Products and Distribution business is recognized for building a disciplined IT and Business Center of Excellence (COE) that standardizes best practices and drives scalable capabilities — positioning Kinaxis for optimal use within supply chain operations. By connecting business and IT, the COE helps drive real-time visibility, more proactive decision-making and improved service levels for customers.

“Our customers continue to set the pace for what modern supply chains can achieve,” said Mike Mauger, Chief Customer Officer at Kinaxis. “Each of this year’s winners is translating strategy into execution and leveraging Kinaxis Maestro to drive faster decisions, improve resilience, and deliver measurable outcomes across their operations. What stands out is not just their innovation, but their ability to turn that innovation into real impact for their business, their customers, and their industries. We are proud to play a part in their success.”

Partner Excellence Supporting Customer Success

Kinaxis also continues to invest in its partner ecosystem, an essential force behind customer success and innovation. Earlier this year at the annual Ignite Sales Kickoff event in Fort Lauderdale, Florida, Kinaxis honored its top partners for outstanding performance and collaboration in 2025:

Top Global System Integrator: Genpact
Top Strategic Partner: 4flow
Top VAR Partner: Deloitte EMEA

Shaping the Future of Supply Chain Together

Kinexions is the premier gathering for the global supply chain community and brings together a community of innovators, leaders, and experts committed to advancing the future of supply chain planning and orchestration. This year’s award winners reflect a broader industry shift toward smarter, faster, and more connected decision-making, powered by AI, real-time data, and end-to-end orchestration.

To learn more about how Kinaxis is revolutionizing supply chain planning and orchestration with AI, please visit Kinaxis.com.

About Kinaxis

Kinaxis is a leader in modern supply chain planning and orchestration, powering complex global supply chains, and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.

Source: Kinaxis Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260604952189/en/

Contacts

Media Relations
Erin Boyle | Kinaxis
eboyle@kinaxis.com
+1 519-574-4065

Investor Relations
Rick Wadsworth | Kinaxis
rwadsworth@kinaxis.com
613-907-7613

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press Release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press Release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye